Plecanatide
- Generic Name
- Plecanatide
- Brand Names
- Trulance
- Drug Type
- Small Molecule
- Chemical Formula
- C65H104N18O26S4
- CAS Number
- 467426-54-6
- Unique Ingredient Identifier
- 7IK8Z952OK
- Background
Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
- Indication
Plecanatide is indicated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adult patients.
- Associated Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C), Chronic idiopathic constipation (CIC)
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-07-11
- Target Recruit Count
- 648
- Registration Number
- NCT05151328
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
GCC Agonist Signal in the Small Intestine
- Conditions
- Malignant Digestive System NeoplasmBarrett EsophagusGastroesophageal Reflux Disease
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Esophagogastroduodenoscopy
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 43
- Registration Number
- NCT05107219
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)
- Conditions
- Irritable Bowel Syndrome With Constipation
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT03596905
- Locations
- 🇺🇸
Synergy Research Site, Newport News, Virginia, United States
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
- Conditions
- Chronic Idiopathic Constipation
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03551873
- Locations
- 🇺🇸
Synergy Research Center 001, Raleigh, North Carolina, United States
🇺🇸Synergy Research Center 002, North Hollywood, California, United States
🇺🇸Syergy Research Center 003, Tamarac, Florida, United States
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT03120520
- Locations
- 🇺🇸
Synergy Research Site, Newport News, Virginia, United States
Long Term Safety Study of Plecanatide
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 2272
- Registration Number
- NCT02706483
- Locations
- 🇺🇸
Synergy Research Site, Milwaukee, Wisconsin, United States
🇺🇸Synergy Research Site., Charlotte, North Carolina, United States
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1135
- Registration Number
- NCT02493452
- Locations
- 🇺🇸
Synergy Research Site, La Crosse, Wisconsin, United States
🇺🇸Synergy Research Site., Orlando, Florida, United States
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1054
- Registration Number
- NCT02387359
- Locations
- 🇺🇸
Synergy Research Site, Wauwatosa, Wisconsin, United States
🇺🇸Synergy Research Site., Nashville, Tennessee, United States
12-Week Study of Plecanatide for CIC (The National CIC3 Study)
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1410
- Registration Number
- NCT02122471
- Locations
- 🇺🇸
Synergy Research Site, Richland, Washington, United States
12-Week Study of Plecanatide for CIC (The CIC3 Study)
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1394
- Registration Number
- NCT01982240
- Locations
- 🇨🇦
Synergy Research Site, St-Romuald, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.